Granted Patent B2

US 7,829,537 · App. 12/508,956 · Granted Nov 9, 2010

Abstract

Claims (13)

1. A conjugate comprising a receptor associated protein (RAP) polypeptide and a therapeutic or diagnostic/investigational agent, wherein the RAP polypeptide consists of an amino acid sequence at least 80% identical to amino acids 221-323 of RAP (SEQ ID NO: 1).

2. The conjugate of claim 1 , wherein the therapeutic agent is a chemotherapeutic agent.

3. The conjugate of claim 2 , wherein the chemotherapeutic agent is selected from the group consisting of an alkylating agent, an alkaloid, an anti-metabolite, an antibiotic, and an anti-proliferative agent.

4. The conjugate of claim 3 , wherein the chemotherapeutic agent is selected from the group consisting of Mechlorethamine hydrochloride, Cyclophosphamide, Ifosfamide, Chlorambucil, Melphalan, Busulfan, Thiotepa (Triethylenethiophosphoramide), Carmustine, Lomustine, Streptozocin, Vincristine, Vinblastine, Paclitaxel, Methotrexate, Mercaptopurine, Thioguanine, Fluorouracil, Cytarabine, Azacitidine, Dactinomycin, Doxorubicin, Daunorubicin, Idarubicin, Bleomycin, Picamycin, Mitomycin, Hydroxyurea, Procarbazine, Dacarbazine, Cisplatin, Carboplatin, Asparaginase, Etoposide, Amsarcrine, Mitotane, and Mitoxantrone.

5. The conjugate of claim 1 , wherein the therapeutic agent is a neurotrophic factor.

6. The conjugate of claim 5 , wherein the therapeutic agent is a neurotrophic factor selected from the group consisting of Glial-Derived Neurotrophic Factor, Nerve Growth Factor, Brain-Derived Neurotrophic Factor, Neurotrophin-3, Neurotrophin-4/5, aFGF, bFGF, CNTF, Leukemia Inhibitory Factor, Cardiotrophin-1, TGFβ, BMPs, GDFs, Neurturin, Artemin, Persephin, EGF, TGFα, Neuregulins, IGF-1, IGF-2, ADNF and PDGF.

7. The conjugate of claim 6 , wherein the therapeutic agent is brain-derived neurotrophic factor (BDNF).

8. The conjugate of claim 2 , wherein the agent is a diagnostic/investigational agent and comprises a detectable label.

9. The conjugate of claim 1 , wherein the agent is conjugated to the RAP amino acid sequence via covalent bonding.

10. The conjugate of claim 1 , wherein the agent is conjugated to the RAP amino acid sequence via a peptide linker.

11. The conjugate of claim 1 , wherein said RAP polypeptide is further missing the endoplasmic reticulum retention signal at residues 320-323 of SEQ ID NO: 1.

12. The conjugate of claim 1 , wherein the conjugate is a fusion protein of the RAP polypeptide and a therapeutic agent.

13. A sterile composition comprising the conjugate of any one of claim 1 , 2 , 3 or 5 and a pharmaceutically acceptable carrier.

Assignments (10)